Two-step enhanced cancer immunotherapy with engineered Salmonella typhimurium secreting heterologous flagellin
The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.
Abstract
Engineered Salmonella secreting heterologous bacterial flagellin suppress tumor growth by activating intratumoral macrophages.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
From The microbiome and human cancer (2021) · cites this paper as [152]
Citations
Cites
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 1×
“INTRODUCTION Abnormal blood vessels and hypoxic and necrotic regions are universal features of solid tumors (1, 2).”
BackgroundKigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3257-09.2009 · Cited by 2,130 · cited 1×
“The engrafted MC38 tumor tissues were removed from C57BL/6 WT mice 24 hours after induction of FlaB and triple-stained with CD45, F4/80, and CD206 (to detect M2-type macrophages) or with CD45, F4/80, and CD86 (to detect M1-type macrophages) (32, 33).”
MethodTargeted Disruption of the MyD88 Gene Results in Loss of IL-1- and IL-18-Mediated Function
Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,041 · cited 1×
“TLR4, TLR5, and MyD88 knockout mice with a C57BL/6 genetic background were described previously (47, 48).”
MethodMolecular Mechanisms That Influence the Macrophage M1–M2 Polarization Balance
Wang, N., Liang, H., & Zen, K. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00614 · Cited by 1,980 · cited 10×
“The in vitro stimulation of cancer cells with FlaB did not increase phosphorylation of NF-kB p65 (fig.”
BackgroundInfluentialThe Isolation and Characterization of Murine Macrophages
Zhang, X., Goncalves, R., & Mosser, D. M. (2008) · Current Protocols in Immunology · doi:10.1002/0471142735.im1401s83 · Cited by 1,536 · cited 1×
“Cell preparation and FACS analysis Peritoneal macrophages were isolated from specific pathogen–free C57BL/6 male mice, as described previously (50).”
MethodToll-like receptors and cancer
Rakoff-Nahoum, S., & Medzhitov, R. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2541 · Cited by 925
Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers
Saito, T., Nishikawa, H., Wada, H., Nagano, Y., Sugiyama, D., Atarashi, K., Maeda, Y., Hamaguchi, M., Ohkura, N., Sato, E., et al. (2016) · Nature Medicine · doi:10.1038/nm.4086 · Cited by 871 · cited 1×
“Because the background signals in experimental groupswere different, whichmay be due to different degrees of cell injury resulting from the different modes of treatment (PBS, empty Salmonella, and FlaB-secreting Salmonella), we adjusted gating parameters for the FACS analysis of different groups (51, 52).”
MethodTherapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869 · cited 1×
“Because of accumulating reports that activating various TLRs resulted in antitumor effects (31, 37–41), many TLRspecific agonists are currently being investigated for tumor immunotherapy (37).”
BackgroundBiswas, S. K. (2006) · Blood · doi:10.1182/blood-2005-01-0428 · Cited by 696
Toso, J. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.142 · Cited by 614 · cited 1×
“VNP20009, an attenuated strainof Salmonella typhimurium with purI and msbB gene deletions, was safely administered to patients with metastatic melanoma and renal cell carcinoma in a phase 1 study, where substantial tumor colonization was observed (11, 12).”
Research works printed but not linked: 1
- 10.1200/jco.2002.20.1.142 · DOI · Paper page
Cited by
Molecular principles of metastasis: a hallmark of cancer revisited
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0134-x · Cited by 2,379
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
“5B), with intratumoral or intravenous injection often leading to ~10,000-fold accumulation in tumors relative to matched liver, spleen, and lung tissues (152, 153).”
BackgroundThe microbiome, cancer, and cancer therapy
Helmink, B. A., Khan, M. A. W., Hermann, A., Gopalakrishnan, V., & Wargo, J. A. (2019) · Nature Medicine · doi:10.1038/s41591-019-0377-7 · Cited by 1,200
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 840
“reported development of a dual TLR4/5 stimulating bacterial cell therapy (BCT) based on attenuated ΔppGpp Salmonella typhimurium (TLR4 agonist) with inducible production of Vibrio vulnificus flagellin B (FlaB, TLR5 agonist) [167].”
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Programmable bacteria induce durable tumor regression and systemic antitumor immunity
Chowdhury, S., Castro, S., Coker, C., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2019) · Nature Medicine · doi:10.1038/s41591-019-0498-z · Cited by 724
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Gurbatri, C. R., Lia, I., Vincent, R., Coker, C., Castro, S., Treuting, P. M., Hinchliffe, T. E., Arpaia, N., & Danino, T. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax0876 · Cited by 647
Therapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
“164 Summarily, bacteria have several advantages as potential carriers for anti-cancer drugs or gene vaccine delivery.”
BackgroundBacteria-cancer interactions: bacteria-based cancer therapy
Duong, M. T.-Q., Qin, Y., You, S.-H., & Min, J.-J. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0297-0 · Cited by 519
Self-citationEngineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Identification of bacteria-derived HLA-bound peptides in melanoma
Kalaora, S., Nagler, A., Nejman, D., Alon, M., Barbolin, C., Barnea, E., Ketelaars, S. L. C., Cheng, K., Vervier, K., Shental, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03368-8 · Cited by 457
Engineering bacteria as interactive cancer therapies
Gurbatri, C. R., Arpaia, N., & Danino, T. (2022) · Science · doi:10.1126/science.add9667 · Cited by 447
Bacterial flagellin—a potent immunomodulatory agent
Hajam, I. A., Dar, P. A., Shahnawaz, I., Jaume, J. C., & Lee, J. H. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.172 · Cited by 387
Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer
Li, C., Xu, X., Wei, S., Jiang, P., Xue, L., & Wang, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001341 · Cited by 360
Optically-controlled bacterial metabolite for cancer therapy
Zheng, D.-W., Chen, Y., Li, Z.-H., Xu, L., Li, C.-X., Li, B., Fan, J.-X., Cheng, S.-X., & Zhang, X.-Z. (2018) · Nature Communications · doi:10.1038/s41467-018-03233-9 · Cited by 324
Bacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Gut Microbiota in Cancer Immune Response and Immunotherapy
Zhou, C.-B., Zhou, Y.-L., & Fang, J.-Y. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.01.010 · Cited by 301
Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer
Gao, Y., Bi, D., Xie, R., Li, M., Guo, J., Liu, H., Guo, X., Fang, J., Ding, T., Zhu, H., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00795-x · Cited by 290
Self-citationDisruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
Staedtke, V., Bai, R.-Y., Kim, K., Darvas, M., Davila, M. L., Riggins, G. J., Rothman, P. B., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2018) · Nature · doi:10.1038/s41586-018-0774-y · Cited by 277
Kuerban, K., Gao, X., Zhang, H., Liu, J., Dong, M., Wu, L., Ye, R., Feng, M., & Ye, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.02.002 · Cited by 277
Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer
Yi, X., Zhou, H., Chao, Y., Xiong, S., Zhong, J., Chai, Z., Yang, K., & Liu, Z. (2020) · Science Advances · doi:10.1126/sciadv.aba3546 · Cited by 276
“typhimurium prepared by the reported method (25) was obtained from the Third Xiangya Hospital of Central South University and stored at −80°C.”
Probiotic-guided CAR-T cells for solid tumor targeting
Vincent, R. L., Gurbatri, C. R., Li, F., Vardoshvili, A., Coker, C., Im, J., Ballister, E. R., Rouanne, M., Savage, T., de los Santos-Alexis, K., et al. (2023) · Science · doi:10.1126/science.add7034 · Cited by 273
Yue, Y., Xu, J., Li, Y., Cheng, K., Feng, Q., Ma, X., Ma, N., Zhang, T., Wang, X., Zhao, X., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00886-2 · Cited by 264
Ultrasound-controllable engineered bacteria for cancer immunotherapy
Abedi, M. H., Yao, M. S., Mittelstein, D. R., Bar-Zion, A., Swift, M. B., Lee-Gosselin, A., Barturen-Larrea, P., Buss, M. T., & Shapiro, M. G. (2022) · Nature Communications · doi:10.1038/s41467-022-29065-2 · Cited by 260
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Intratumoural microbiota: a new frontier in cancer development and therapy
Cao, Y., Xia, H., Tan, X., Shi, C., Ma, Y., Meng, D., Zhou, M., Lv, Z., Wang, S., & Jin, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01693-0 · Cited by 253
Microbiota in Tumors: From Understanding to Application
Xie, Y., Xie, F., Zhou, X., Zhang, L., Yang, B., Huang, J., Wang, F., Yan, H., Zeng, L., Zhang, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202200470 · Cited by 209
Synthetic biomarkers: a twenty-first century path to early cancer detection
Kwong, G. A., Ghosh, S., Gamboa, L., Patriotis, C., Srivastava, S., & Bhatia, S. N. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00389-3 · Cited by 209
Exploiting bacteria for cancer immunotherapy
Kwon, S.-Y., Thi-Thu Ngo, H., Son, J., Hong, Y., & Min, J.-J. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00908-9 · Cited by 201
Self-citationChen, Y., Du, M., Yuan, Z., Chen, Z., & Yan, F. (2022) · Nature Communications · doi:10.1038/s41467-022-31932-x · Cited by 189
Sun, R., Liu, M., Lu, J., Chu, B., Yang, Y., Song, B., Wang, H., & He, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-32837-5 · Cited by 188
Applications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G.-Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 179
Technology Roadmap of Micro/Nanorobots
Ju, X., Chen, C., Oral, Ç. M., Sevim, S., Golestanian, R., Sun, M., Bouzari, N., Lin, X., Urso, M., Nam, J. S., et al. (2025) · ACS Nano · doi:10.1021/acsnano.5c03911 · Cited by 175
Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors
Wang, H., Najibi, A. J., Sobral, M. C., Seo, B. R., Lee, J. Y., Wu, D., Li, A. W., Verbeke, C. S., & Mooney, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19540-z · Cited by 172
Raman, V., Van Dessel, N., Hall, C. L., Wetherby, V. E., Whitney, S. A., Kolewe, E. L., Bloom, S. M. K., Sharma, A., Hardy, J. A., Bollen, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26367-9 · Cited by 171
Bioengineering of bacteria for cancer immunotherapy
Nguyen, D.-H., Chong, A., Hong, Y., & Min, J. (2023) · Nature Communications · doi:10.1038/s41467-023-39224-8 · Cited by 169
Self-citationBacteria and bacterial derivatives as drug carriers for cancer therapy
Cao, Z., & Liu, J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.009 · Cited by 167
The twin cytokines interleukin-34 and CSF-1: masterful conductors of macrophage homeostasis
Muñoz-García, J., Cochonneau, D., Télétchéa, S., Moranton, E., Lanoé, D., Brion, R., Lézot, F., Heymann, M., & Heymann, D. (2020) · Theranostics · doi:10.7150/thno.50683 · Cited by 167
“These changes in tumor microenvironment induced a reduction of tumor growth [224].”
BackgroundMethodZheng, D., Deng, W., Song, W., Wu, C., Liu, J., Hong, S., Zhuang, Z., Cheng, H. L., Sun, Z., & Zhang, X. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00807-9 · Cited by 166
Self-citationEngineering probiotics for therapeutic applications: recent examples and translational outlook
Aggarwal, N., Breedon, A. M. E., Davis, C. M., Hwang, I. Y., & Chang, M. W. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2020.02.016 · Cited by 154
The microbiome and the hallmarks of cancer
Fulbright, L. E., Ellermann, M., & Arthur, J. C. (2017) · PLOS Pathogens · doi:10.1371/journal.ppat.1006480 · Cited by 164
Enhancing the tropism of bacteria via genetically programmed biosensors
Chien, T., Harimoto, T., Kepecs, B., Gray, K., Coker, C., Hou, N., Pu, K., Azad, T., Nolasco, A., Pavlicova, M., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00772-3 · Cited by 164
Genetically engineered Salmonella Typhimurium: Recent advances in cancer therapy
Liang, K., Liu, Q., Li, P., Luo, H., Wang, H., & Kong, Q. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.037 · Cited by 154
Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity
Ozdemir, T., Fedorec, A. J. H., Danino, T., & Barnes, C. P. (2018) · Cell Systems · doi:10.1016/j.cels.2018.06.008 · Cited by 159
Song, C., Phuengkham, H., Kim, Y. S., Dinh, V. V., Lee, I., Shin, I. W., Shin, H. S., Jin, S. M., Um, S. H., Lee, H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11730-8 · Cited by 159
Tweak to Treat: Reprograming Bacteria for Cancer Treatment
Sieow, B. F.-L., Wun, K. S., Yong, W. P., Hwang, I. Y., & Chang, M. W. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2020.11.004 · Cited by 158
Engineered probiotics biofilm enhances osseointegration via immunoregulation and anti-infection
Tan, L., Fu, J., Feng, F., Liu, X., Cui, Z., Li, B., Han, Y., Zheng, Y., Yeung, K. W. K., Li, Z., et al. (2020) · Science Advances · doi:10.1126/sciadv.aba5723 · Cited by 155
Synthetic gene circuits for the detection, elimination and prevention of disease
Sedlmayer, F., Aubel, D., & Fussenegger, M. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0215-0 · Cited by 151
Recent Progress and Trends in X-ray-Induced Photodynamic Therapy with Low Radiation Doses
He, L., Yu, X., & Li, W. (2022) · ACS Nano · doi:10.1021/acsnano.2c07286 · Cited by 151
Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity
Zhou, Y., Shen, G., Zhou, X., & Li, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02242-7 · Cited by 149
Bacterial Therapy of Cancer: Promises, Limitations, and Insights for Future Directions
Kramer, M. G., Masner, M., Ferreira, F. A., & Hoffman, R. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00016 · Cited by 145
“the actual location of transgene expression would allow the right selection of the gene, promoter, and secretion system (if required) to achieve optimized therapy (Forbes, 2010; Zheng et al., 2017).”
BackgroundInfluentialSynthetic genetic circuits for programmable biological functionalities
Xia, P., Ling, H., Foo, J. L., & Chang, M. W. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.015 · Cited by 141
Theranostic cells: emerging clinical applications of synthetic biology
McNerney, M. P., Doiron, K. E., Ng, T. L., Chang, T. Z., & Silver, P. A. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00383-3 · Cited by 141
Bacterial-based cancer therapy: An emerging toolbox for targeted drug/gene delivery
Lin, D., Feng, X., Mai, B., Li, X., Wang, F., Liu, J.-X., Liu, X., Zhang, K., & Wang, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121124 · Cited by 141
Bacterial therapies at the interface of synthetic biology and nanomedicine
Hahn, J., Ding, S., Im, J., Harimoto, T., Leong, K. W., & Danino, T. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00119-4 · Cited by 139
Bacteria-Mediated Synergistic Cancer Therapy: Small Microbiome Has a Big Hope
Lou, X., Chen, Z., He, Z., Sun, M., & Sun, J. (2021) · Nano-Micro Letters · doi:10.1007/s40820-020-00560-9 · Cited by 138
Designer probiotics for the prevention and treatment of human diseases
Chua, K. J., Kwok, W. C., Aggarwal, N., Sun, T., & Chang, M. W. (2017) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2017.04.011 · Cited by 137
Xu, J., Ma, Q., Zhang, Y., Fei, Z., Sun, Y., Fan, Q., Liu, B., Bai, J., Yu, Y., Chu, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27750-2 · Cited by 129
Progress of engineered bacteria for tumor therapy
Fan, J.-X., Niu, M.-T., Qin, Y.-T., Sun, Y.-X., & Zhang, X.-Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114296 · Cited by 120
Chang, Z., Guo, X., Li, X., Wang, Y., Zang, Z., Pei, S., Lu, W., Li, Y., Huang, J., Xiao, Y., et al. (2025) · Cell · doi:10.1016/j.cell.2025.02.002 · Cited by 129
Yang, Z., Zhu, Y., Dong, Z., Hao, Y., Wang, C., Li, Q., Wu, Y., Feng, L., & Liu, Z. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121332 · Cited by 122
Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium
Guo, Y., Chen, Y., Liu, X., Min, J.-J., Tan, W., & Zheng, J. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.033 · Cited by 124
Self-citationCellular Biosensors with Engineered Genetic Circuits
Saltepe, B., Kehribar, E. Ş., YİRMİBEŞOĞLU, S. S. S., & Şeker, U. Ö. Ş. (2017) · ACS Sensors · doi:10.1021/acssensors.7b00728 · Cited by 121
Synthetic biology-inspired cell engineering in diagnosis, treatment and drug development
Zhao, N., Song, Y., Xie, X., Zhu, Z., Duan, C., Nong, C., Wang, H., & Bao, R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01375-x · Cited by 121
Gupta, K. H., Nowicki, C. A., Giurini, E. F., Marzo, A. L., & Zloza, A. (2021) · Vaccines · doi:10.3390/vaccines9121497 · Cited by 120
“SHJ2037 ∆relA/∆spoT ∆ppGpp (global regulator); reduction in bacterial invasion [149,150]”
BackgroundMacrophage based drug delivery: Key challenges and strategies
Guo, Q., & Qian, Z. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.04.004 · Cited by 120
“On the other hand, they are driven toward inflammatory cells and immunosuppressive tumor-associated macrophages, leading to tissue damage and pathology [10,11].”
BackgroundAdvances in bacterial cancer therapies using synthetic biology
Chien, T., Doshi, A., & Danino, T. (2017) · Current Opinion in Systems Biology · doi:10.1016/j.coisb.2017.05.009 · Cited by 119
Cell/Bacteria‐Based Bioactive Materials for Cancer Immune Modulation and Precision Therapy
Pan, H., Zheng, M., Ma, A.-Q., Liu, L., & Cai, L. (2021) · Advanced Materials · doi:10.1002/adma.202100241 · Cited by 115
Customized materials-assisted microorganisms in tumor therapeutics
Chen, Q., Qiao, J., Liu, X., Zhang, C., & Zhang, X. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01571g · Cited by 110
Engineered Bacteria for Enhanced Radiotherapy against Breast Carcinoma
Pan, P., Dong, X., Chen, Y., Zeng, X., & Zhang, X. (2022) · ACS Nano · doi:10.1021/acsnano.1c08350 · Cited by 110
Bacteria and bacterial derivatives as delivery carriers for immunotherapy
Kang, S., Nguyen, D.-H., Yoo, S. W., & Min, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114085 · Cited by 106
Self-citationBiomaterial‐Based In Situ Cancer Vaccines
Yang, B., & Wang, H. (2023) · Advanced Materials · doi:10.1002/adma.202210452 · Cited by 105
Yu, L., Liu, Z., Xu, W., Jin, K., Liu, J., Zhu, X., Zhang, Y., & Wu, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.007 · Cited by 105
“Bacteria administered intratumorally or intravenously accumulate substantially more in tumors than in other tissues 151 .”
BackgroundNear‐Infrared Nano‐Optogenetic Activation of Cancer Immunotherapy via Engineered Bacteria
Zhu, X., Chen, S., Hu, X., Zhao, L., Wang, Y., Huang, J., Chen, J., Qiu, Y., Zhang, X., Wang, M., et al. (2022) · Advanced Materials · doi:10.1002/adma.202207198 · Cited by 103
Li, M., Liu, N., Zhu, J., Wu, Y., Niu, L., Liu, Y., Chen, L., Bai, B., Miao, Y., Yang, Y., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2024.122584 · Cited by 103
Tumor-associated macrophage polarization in the inflammatory tumor microenvironment
Zou, Z., Lin, H., Li, M., & Lin, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103149 · Cited by 100
“Other TLR agonists have also been found to alter f M2 TAMs to pro-inflammatory M1 phenotype and promote tumor regression in mouse models (84).”
BackgroundThe Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy
Cogdill, A. P., Gaudreau, P. O., Arora, R., Gopalakrishnan, V., & Wargo, J. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.09.007 · Cited by 98
Promising dawn in tumor microenvironment therapy: engineering oral bacteria
Wang, Z., Sun, W., Hua, R., Wang, Y., Li, Y., & Zhang, H. (2024) · International Journal of Oral Science · doi:10.1038/s41368-024-00282-3 · Cited by 97
Oral delivery of bacteria: Basic principles and biomedical applications
Li, S., Jiang, W., Zheng, C., Shao, D., Liu, Y., Huang, S., Han, J., Ding, J., Tao, Y., & Li, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.011 · Cited by 97
Targeting tumor‐associated macrophages: A potential treatment for solid tumors
Chen, Y., Jin, H., Song, Y., Huang, T., Cao, J., Tang, Q., & Zou, Z. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30139 · Cited by 82
Tumor Targeting by Fusobacterium nucleatum: A Pilot Study and Future Perspectives
Abed, J., Maalouf, N., Parhi, L., Chaushu, S., Mandelboim, O., & Bachrach, G. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00295 · Cited by 94
“, 2011), and additional bacterial species are being explored for future cancer treatment (Quispe-Tintaya et al., 2013; Zheng et al., 2017).”
BackgroundTan, W., Duong, M. T.-Q., Zuo, C., Qin, Y., Zhang, Y., Guo, Y., Hong, Y., Zheng, J. H., & Min, J.-J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.023 · Cited by 84
Self-citationDesign of Outer Membrane Vesicles as Cancer Vaccines: A New Toolkit for Cancer Therapy
Zhang, Y., Fang, Z., Li, R., Huang, X., & Liu, Q. (2019) · Cancers · doi:10.3390/cancers11091314 · Cited by 93
Bacteria-based immunotherapy for cancer: a systematic review of preclinical studies
Zhou, M., Tang, Y., Xu, W., Hao, X., Li, Y., Huang, S. Q., Xiang, D., & Wu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1140463 · Cited by 92
“(Figure 1) Some engineered bacterial therapeutics, such as Salmonella coated with allylamine hydrochloride and engineered FlaB-secreting bacteria, are colonized in TEM to promote the infiltration of numerous macrophages and neutrophils (49, 82).”
BackgroundSequence-Based Characterization of Intratumoral Bacteria—A Guide to Best Practice
Walker, S. P., Tangney, M., & Claesson, M. J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00179 · Cited by 91
Compartmentalized Antimicrobial Defenses in Response to Flagellin
Vijayan, A., Rumbo, M., Carnoy, C., & Sirard, J. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.008 · Cited by 90
Mi, Z., Guo, L., Liu, P., Qi, Y., Feng, Z., Liu, J., He, Z., Yang, X. H., Jiang, S., Wu, J., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.0c03811 · Cited by 88
Self-citationWang, Y., Shi, J., Xin, M., Kahkoska, A. R., Wang, J., & Gu, Z. (2024) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01230-6 · Cited by 88
“Bacteria-induced inflammation can contribute to antitumour immunity 104,105 (notably, Salmonella typhimurium can kill tumour cells directly, or indirectly by activating CD8 + T cells and natural killer cells 106,107 ).”
Mi, Z., Yao, Q., Qi, Y., Zheng, J., Liu, J., Liu, Z., Tan, H., Ma, X., Zhou, W., & Rong, P. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.016 · Cited by 86
Self-citationBose, R. J. C., Tharmalingam, N., Garcia Marques, F. J., Sukumar, U. K., Natarajan, A., Zeng, Y., Robinson, E., Bermudez, A., Chang, E., Habte, F., et al. (2020) · ACS Nano · doi:10.1021/acsnano.0c00921 · Cited by 84
Influence of gut and intratumoral microbiota on the immune microenvironment and anti-cancer therapy
Chen, Y., Liu, B., Wei, Y., & Kuang, D.-M. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105966 · Cited by 73
Chen, J., Qiao, Y., Chen, G., Chang, C., Dong, H., Tang, B., Cheng, X., Liu, X., & Hua, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.04.019 · Cited by 83
Bacterially mediated drug delivery and therapeutics: Strategies and advancements
Wu, L., Bao, F., Li, L., Yin, X., & Hua, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114363 · Cited by 83
Harnessing bacteria for tumor therapy: Current advances and challenges
Guo, L., Ding, J., & Zhou, W. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108557 · Cited by 83
Dróżdż, M., Makuch, S., Cieniuch, G., Woźniak, M., & Ziółkowski, P. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118296 · Cited by 77
Therapeutic Targeting of Signaling Pathways Related to Cancer Stemness
Espinosa-Sánchez, A., Suárez-Martínez, E., Sánchez-Díaz, L., & Carnero, A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01533 · Cited by 71
Cancer vaccines: Target antigens, vaccine platforms and preclinical models
Ruzzi, F., Riccardo, F., Conti, L., Tarone, L., Semprini, M. S., Bolli, E., Barutello, G., Quaglino, E., Lollini, P., & Cavallo, F. (2024) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2024.101324 · Cited by 81
Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer
Moradi‐Marjaneh, R., Hassanian, S. M., Fiuji, H., Soleimanpour, S., Ferns, G. A., Avan, A., & Khazaei, M. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26273 · Cited by 81
“Moreover the authors showed that the TLR4 and TLR5 signaling pathways mediate these anticancer effects (Zheng et al., 2017).”
Background
Metadata
- Authors
- Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., Choy, H. E., Lee, S. E., Rhee, J. H., & Min, J.-J.
- Affiliations
- Chonnam National University (KR)
- City Of Hope National Medical Center (US)
- Department of Nuclear Medicine, Chonnam National University Medical School, Gwangju 61469, Republic of Korea.
- Korea Research Institute of Bioscience and Biotechnology (KR)
- Corresponding author
- Rhee, Joon Haeng
- Min, Jung-Joon
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-08
- Volume
- 9
- Issue
- 376
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2586223583
- Cited by
- 588
- References
- 54
- Citations by year
- 2026: 76 · 2025: 81 · 2024: 85 · 2023: 73 · 2022: 71 · 2021: 65 · 2020: 55 · 2019: 34 · 2018: 30 · 2017: 18
- FWCI
- 27.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- KRIBB Repository (submittedVersion)
- Funders
- Pioneer Research Center Program (2015M3C1A3056410)
- Bio & Medical Technology Development Program (NRF-2014M3A9B5073747)
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
- NRF (2012-0006072)
- Ministry of Health and Welfare, Republic of Korea (HI14C0187)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunotherapy, Salmonella typhimurium, tumor-targeting bacteria, intratumoral macrophages, M1 macrophage polarization, TLR ligands
- MeSH terms
- Animals, Colonic Neoplasms, Flagellin, Genetic Engineering, Humans, Immunotherapy, Macrophages, Male, Mice, Inbred C57BL, Mice, Nude, Neoplasm Metastasis, Neoplasms, Phenotype, Salmonella typhimurium, Colony Count, Microbial, Signal Transduction, Cell Polarity, Xenograft Model Antitumor Assays, HCT116 Cells, Toll-Like Receptor 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.